CTOs on the Move

GeneGo bioinformatics software

www.genego.com

 
GeneGo bioinformatics software is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.genego.com
  • 500 Renaissance Dr #106
    Saint Joseph, MI USA 49085
  • Phone: 888.592.3124

Executives

Name Title Contact Details

Similar Companies

Stealth BioTherapeutics

Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.

AlgiKnit

AlgiKnit is a collective of designers and scientists who work across disciplines to create new material possibilities. Were creating sustainable, algae-derived, biodegradable yarns and textiles to remediate harmful cycles of fast fashion. Bui...

ASD BioSystems Inc

ASD BioSystems Inc is a Gretna, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.

Ecomark

Ecomark Ltd is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.